These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3504244)

  • 21. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. For better or worse: The effect of levodopa on speech in Parkinson's disease.
    Ho AK; Bradshaw JL; Iansek R
    Mov Disord; 2008 Mar; 23(4):574-80. PubMed ID: 18163453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease. Diagnosis and the initiation of therapy.
    Bhat V; Weiner WJ
    Minerva Med; 2005 Jun; 96(3):145-54. PubMed ID: 16175158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced Parkinson's disease.
    Diamond A; Jankovic J
    Expert Rev Neurother; 2006 Aug; 6(8):1181-97. PubMed ID: 16893346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A family of parkinsonism in which the clinical feature of constituents varied with the age of onset].
    Sasaki R; Kuzuhara S; Taniguchi A; Narita Y; Naito Y
    Rinsho Shinkeigaku; 1994 Jul; 34(7):736-8. PubMed ID: 7955737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glottographic measures before and after levodopa treatment in Parkinson's disease.
    Jiang J; Lin E; Wang J; Hanson DG
    Laryngoscope; 1999 Aug; 109(8):1287-94. PubMed ID: 10443835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions.
    van Zagten M; Lodder J; Kessels F
    Mov Disord; 1998 Jan; 13(1):89-95. PubMed ID: 9452332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced Parkinson's disease by subthalamotomy: one-year results.
    Su PC; Tseng HM; Liu HM; Yen RF; Liou HH
    Mov Disord; 2003 May; 18(5):531-8. PubMed ID: 12722167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnosis of manganese-induced parkinsonism.
    Cersosimo MG; Koller WC
    Neurotoxicology; 2006 May; 27(3):340-6. PubMed ID: 16325915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
    Parkes JD; Marsden CD; Rees JE; Curzon G; Kantamaneni BD; Knill-Jones R; Akbar A; Das S; Kataria M
    Q J Med; 1974 Jan; 43(169):49-61. PubMed ID: 4822972
    [No Abstract]   [Full Text] [Related]  

  • 38. Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation.
    Romito LM; Contarino MF; Vanacore N; Bentivoglio AR; Scerrati M; Albanese A
    Mov Disord; 2009 Mar; 24(4):557-63. PubMed ID: 19097175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The deterioration of patients with parkinsonism treated with L-dopa].
    Guillard A
    Nouv Presse Med; 1975 Oct; 4(35):2503-6. PubMed ID: 1196872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinsonism following dystonia in three patients.
    Katchen M; Duvoisin RC
    Mov Disord; 1986; 1(2):151-7. PubMed ID: 3504239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.